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40-word summary 
A 2-arm randomized controlled trial conducted in Indonesia showing that the addition 
of a single dose of primaquine (0.75 mg/kg) shortens the infectivity period of malaria 
patients treated with dihydroartemisinin-piperaquine with normal glucose-6-phosphate 
dehydrogenase (G6PD) enzyme levels. 
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ABSTRACT 
Background. Artemisinin-based combination therapy (ACT) is very effective in 
clearing asexual stages of malaria and reduces gametocytemia, but may not affect 
mature gametocytes. Primaquine is the only commercially available drug that eliminates 
mature gametocytes.  
Methods and objectives. We conducted a two-arm open-label randomized 
controlled trial to evaluate the efficacy of single dose primaquine (0.75 mg/kg) following 
treatment with dihydroartemisinin-piperaquine on P. falciparum’s gametocytemia, in 
Indonesia. Patients with symptomatic uncomplicated falciparum malaria, normal 
glucose-6-phosphate dehydrogenase (G6PD) enzyme levels, aged ≥5 years and 
hemoglobin levels ≥8 g/dL were assigned by computerized-generating sequence to 
receive either a standard 3-day course dihydroartemisinin-piperaquine alone (n=178) or 
combined with a single dose of primaquine on Day-3 (n=171). Patients were seen on 
days 1, 2, 3, 7 and then weekly for 42 days to assess the presence of gametocytes and 
asexual parasites by microscopy. Survival analysis was stratified by the presence of 
gametocytes on Day-3.  
Results. DHP prevented development of gametocytes in 277 patients without 
gametocytes on Day-3. In the gametocytemic patients (n=72), primaquine was 
associated with faster clearance of gametocytes (HR=2.42, 95% CI 1.39- 4.19, P= 0.002) 
and reduced gametocyte densities (geometric mean area-under-the-curve 157 vs 330, P= 
0.018). The Day-42 cure rate of asexual stages in the DHP-PQ and DHP-alone arms 
were: PCR-unadjusted: 98.7% vs 99.4% respectively; PCR-adjusted:100% for both. 
Primaquine was well tolerated. 
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Conclusion. Addition of a single dose of primaquine shortens the infectivity period of 
DHP treated patients with acute uncomplicated malaria and should be considered in 
low transmission regions that aim to control and ultimately eliminate falciparum 
malaria.  
Clinical Trial Registration.  NCT01392014.  
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INTRODUCTION 
The World Health Organization (WHO) recommends that a single dose of primaquine 
be added to standard blood schizonticidal therapy of P. falciparum malaria because of 
its gametocidal effect and potential transmission blocking activity [1]. Primaquine is a 
member of the 8-aminoquinolines approved by the US-based FDA in 1952 and one of 
the older antimalarials still in widespread use. It’s use has received renewed attention 
with the increased interest in malaria elimination [2]. However, the use of primaquine 
to reduce malaria transmission is controversial. Although it only adds $0.05 to the cost 
of therapy [3], primaquine can cause severe and occasionally life-threatening hemolysis 
in patients with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency. 
Moreover, the artemisinins themselves, which are part of artemisinin based 
combination therapy (ACT), are very efficient in inhibiting the growth of asexual stages; 
thereby, indirectly inhibiting the development of P. falciparum gametocytes by reducing 
the asexual stage progenitors [4, 5]. Furthermore, numerous in vitro studies suggest 
that artemisinin derivatives may directly inhibit the development of young P. 
falciparum gametocytes into mature gametocytes [6, 7]. These later stage gametocytes, 
circulate in the peripheral circulation for several weeks to allow ingestion by the 
mosquito vector [8]. Hence, anti-malarial drug treatments that can reduce the 
development of mature gametocytes may play a key role in the elimination of malaria 
transmission. However, some studies suggest that artemisinins alone or in combination 
with other drugs merely reduce the number of immature gametocytes and are not 
effective in eradicating all mature gametocytes; consequently, ACT treated patients may 
remain infectious for 2 to 4 weeks [9-14]. Thus, additional drugs such as PQ, that act 
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directly against mature gametocytes may be beneficial to reduce or eliminate 
transmission in communities [1, 15].  
In Indonesia, dihydroartemisinin-piperaquine (DHP) has been the first-line treatment 
for both uncomplicated P. falciparum and P. vivax infections since 2010. The risk of P. 
falciparum gametocytemia is higher after treatment with DHP than with other ACTs, 
possibly reflecting the relatively lower dose of artemisinins in DHP[16]. The national 
policy also includes the use of a single dose of 0.75 mg/kg primaquine in addition to 
DHP, however, with the exception of the bigger health centers and hospitals, screening 
for G6PD-deficiency is usually unavailable. Further, the effectiveness of primaquine in 
reducing gametocytes has never been evaluated in DHP-treated patients in Indonesia. 
The present trial was designed to determine the risk-benefit profile of a single dose of 
primaquine when given directly following treatment with DHP. 
MATERIALS AND METHODS 
Study site 
The study was conducted between December 2008 and March 2010 at Hanura Primary 
Health Center, Padang Cermin district, Lampung province (105°45'-103°48'E and 3°45'-
6°45'S) located at the southern end of Sumatra. The health center was the only place in 
the immediate area providing artemisinin-based combination drugs for antimalarial 
treatment. Nearby abandoned shrimp cultivation ponds, provide larval habitat  for 
Anopheles sundaicus, an efficient and important malaria vector in the region [17]. 
Seasonal malaria transmission peaks following the rainy season between September and 
April. At the time of the study, artesunate-amodiaquine with a single dose of primaquine 
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was the first-line therapy for patients with P. falciparum infection. High-grade 
chloroquine resistance to both P. falciparum and P. vivax is well-established in the area 
[18]. Community based surveys showed that the study area had low malaria endemicity 
with a malaria prevalence of 1.8% across all age groups at the time of this study (Sutanto 
et al, unpublished).  
Participants 
This was a single center open-label two-arm randomized controlled superiority trial in 
patients with fever or a history of fever within the past 24 hour with microscopically 
confirmed P. falciparum infections, regardless of the presence of gametocyte stages. 
Inclusion criteria consisted of: 1) parasite density≥ 1,000/µL;2) age ≥5 years; 3) normal 
glucose-6-phosphate dehydrogenase (G6PD) enzyme levels based on a qualitative test 
(Trinity Biotech no 203, USA); 4) hemoglobin level ≥ 8 gr/dL (HemocueHb 201+); 5) 
negative pregnancy test (assessed by HCG urine test) or not breastfeeding; 6) no signs of 
severe malnutrition; 7) no other chronic diseases; 8) no history of allergy to the study 
drugs; 9) ability to return for 42-day-follow up. A history of previous antimalarial drug 
use was not an exclusion criterion. The protocol was approved by the Ethical Committee 
of the Faculty of Medicine, University of Indonesia, Jakarta.  
Procedures 
Subjects received a standard 3-day course of DHP (fixed-dose tablets of 40 mg 
dihydroartemisinin and 320 mg piperaquine; D-ARTEPP, Guilin Pharmaceutical Co. , 
Ltd, China) with (DHP-PQ) and without PQ (DHP-alone). The daily DHP regimen was 
based on weight (≥41 kg: 3 tablets; 31-40kg: 2 tablets; 18-30kg: 1 tablet). The total dose 
of dihydroartemisinin ranged from 4-10.9 mg/kg and piperaquine 32-87.3 mg/kg. In 
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the DHP-PQ arm, a single dose of primaquine (PQ, 15 mg base, PT Phapros TbK, 
Jakarta, Indonesia) was given on day 3 to achieve a dose of 0.75 mg/kg, rounded to the 
nearest half tablet. The mean dose was 0.74 mg/kg (range 0.5 to 0.94 mg/kg). Modeling 
has suggested that the greatest impact of primaquine on gametocytes can be achieved by 
administrating primaquine on day 8 after the start of symptoms [19]. However, self-
treatment and corresponding delay in seeking care from health centers is common in 
Indonesia such that many patients attend clinic several days after the onset of 
symptoms. We chose to administer primaquine on day 3 to maximize the delay of 
primaquine administration while minimizing the impact on compliance.  
All treatment doses were given as directly observed therapy by the health-care 
attendants. If the patient vomited within 30 minutes, the same dose was repeated. If 
drug vomiting re-occurred the subject was excluded. Before taking the tablets, each 
subject took biscuits provided by the study.  Both manufacturers provided certificates of 
analysis for the batches used in the study, and fulfilled standards for Good 
Manufacturing Practices in China and Indonesia, respectively.  
Subjects with fever (≥ 38.50C using tympanic membrane measurement) received 
paracetamol. Subjects were requested to return to the health center on Days 1, 2, 3, 7, 
14, 21, 28, 35 & 42 or any other day in between if they felt ill. At each scheduled visit 
(except on Day 1) a finger-prick blood sample was collected for malaria blood smears 
and dried blood blots for parasite genotyping (100 µL of blood on Whatman FTA filter 
paper). Patients found to be parasitemic on day-7 or later were treated with quinine (3 x 
10 mg/kg/day for 7 days). Compliance or outcome following treatment with quinine was 
not monitored.  
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Thick and thin blood smears were stained with 3% Giemsa solution for 40 minutes. The 
number of asexual parasites was counted against 200 leukocytes and expressed per 
microliter assuming a leukocyte count of 8,000 /µL blood. If fewer than 10 parasites 
were detected in the first 200 leukocytes, counting was continued against 500 
leukocytes. If no parasites were detected, 100 fields were examined before a smear was 
declared negative. The counting of sexual stage parasites was always against 500 
leukocytes. Blood smears were read independently by 2 laboratory technicians, in the 
field (unblinded to the treatment allocation) and in the central laboratory in Jakarta 
(blinded). In case of disagreement, a third reader (blinded) reread the slide and final 
results were based on the third reader. Parasite densities were determined using the 
average parasite counts from both technicians. Hemoglobin levels were assessed on 
Days 0, 7 and 42 using a Hemocue (Hb 201+, Angelholm, Sweden). G6PD deficiency 
was defined using qualitative assays based on the fluorescent spot test (Trinity Biotech, 
USA, cat no 203-A). 
Molecular analysis to distinguish reinfections from recrudescences of P. falciparum was 
performed at the Eijkman Institute, Jakarta, by genotyping GLURP, MSP2, and MSP1 in 
paired samples of treatment failures[20, 21].  
Randomization and masking 
A computerized randomization sequence was prepared in advance. Block sizes of four 
were used to ensure equal distribution across the study arms by time. Allocation 
concealment was achieved by using pre-numbered opaque and sealed envelopes. 
Eligible subjects were randomized sequentially by drawing successive envelopes 
according to their order on the patient’s list at the health care.  
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Outcomes and sample size 
The main objective was to determine the effect of the standard single dose of 
primaquine in addition to the completed 3-day treatment with DHP on gametocyte 
carriage. This was done by comparing the overall risk of gametocyte carriages on day-7 
and then weekly till day-42, to measure the combined effect on gametocyte development 
and clearance (primary endpoint). This 2-arm trial required 165 patients per arm to 
detect a 7% absolute reduction in the prevalence of gametocytes following the week after 
treatment with primaquine from 9% in DHP-only arm to 2% in the DHP+PQ arm with 
80% power and a two-sided alpha of 0.05. The anticipated gametocyte prevalence of 9% 
was based on the Day-7 prevalence in an earlier study with DHP (Sutanto et al, 
unpublished observations). We planned to recruit 200 patients per arm, to allow for 
17.5% loss to follow-up, but recruitment was stopped earlier because the success rate of 
follow-up was higher than anticipated. 
We also assessed the impact on gametocytes using the following secondary endpoints: a) 
the gametocyte clearance rates by day-42 in patients with gametocytes on day 3, b) the 
incidence of gametocyte development by day-42 in patients who were gametocyte free 
on the day 3, and c) gametocyte densities between days 3 and 42 inclusive. Other 
endpoints included the effect of primaquine on recurrence of the asexual stages of 
P.falciparum, PCR-adjusted and unadjusted for reinfections.  
Adverse events were evaluated using a questionnaire prompting for symptoms of 
headache, weakness, nausea, vomit, abdominal pain, diarrhea, itching and paresthesia.  
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Statistical analysis 
Modified Intention-To-Treat (mITT) analysis of the effect of primaquine was used and 
the evaluable population included all patients that were seen on Day-3. Patients who 
withdrew, were lost to follow up or had protocol deviations before day 3 were excluded 
from the analysis; however they were included if these events occurred after day 3.  
Data were analyzed using STATA v10.0. Differences in gametocyte prevalence were 
compared using the prevalence ratio (PR) and corresponding 95% confidence interval 
(CI), along with P-values using Chi-square test or Fisher Exact test. The therapeutic 
response to treatment was assessed by calculating the cumulative risks of recurrence of 
asexual parasites (unadjusted and PCR-adjusted for reinfections by genotyping) and 
compared by survival analysis, using the Kaplan-Meier product limit formula[22]. In the 
PCR-unadjusted analysis, recurrences were treated as treatment failures and all other 
events (withdrawal, protocol deviations, occurrence of P. vivax) resulted in censoring at 
the time of that event, or at the time of their last follow-up visit in case of loss to follow-
up. A similar strategy was used for the PCR-adjusted analysis except that patients with 
new P. falciparum infections were censored at the time of parasite reappearance[22]. 
Unadjusted Kaplan Meier survival analysis was also used to compare the cumulative risk 
of gametocyte development in the gametocyte free population on day 3, and to measure 
the risk of persistence of gametocytes or appearance of new gametocytes in those 
gametocytemic on day 3. Similar criteria for censoring were used as for the unadjusted 
analysis of the asexual stages.The difference in area-under-the-curve (AUC) of log 
transformed gametocyte density starting from Day-3 to Day-42 was compared using the 
T-test. Gametocyte densities are presented as the geometric mean (95% CI) and the 
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difference compared by geometric mean ratio (95% CI). Adverse events on Day-7 were 
evaluated among patients without the sign or symptom on Day-3 and differences 
between the two groups compared by the prevalence ratio. Mean hemoglobin levels on 
days 7 and 42 were analyzed with a generalized linear model, adjusted for the baseline 
hemoglobin levels on Day-0 and results expressed as mean difference.  
RESULTS 
Evaluable population 
A total of 374 individuals were randomized; 186 received DHP+PQ and 188 DHP-alone. 
Of the 374, 25 (6.6%) were excluded from analysis (15 and 10 subjects from DHP+PQ 
and DHP-alone groups, respectively (Figure 1). Thus, 171 subjects in the DHP+PQ arm 
and 178 subjects in the DHP-alone arm contributed to the mITT analysis of which 41 
and 31 had gametocytes on Day-3 respectively. Baseline characteristics on Day-3 were 
comparable (Table 1). During the follow up period, 9 and 11 subjects from DHP+PQ and 
DHP-alone groups were censored (7 took prohibited drugs, 10 moved from the study 
area, 3 withdrew from the study). 
Gametocyte responses 
The prevalence of gametocytemia was slightly, but not significantly higher among the 
DHP-PQ group on Day-3 just prior to the administration of primaquine (PR=1.38, 95% 
CI 0.91-2.09, P= 0.13). By Day-7 (4 days after PQ administration), the ratio had changed 
to PR=0.93 (95% CI 0.54-1.58, P= 0.78), and by Day-14 the prevalence of gametocytes 
in primaquine group was 16.6-fold lower than in the DHP-alone arm (PR=0.06, 95% CI 
0.01-0.47, P<0.0001) (Figure 2). No-one developed microscopically patent gametocytes 
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among the patients who were gametocyte free on Day-3. Among those who were 
gametocytemic on Day-3, patients in the DHP-alone group remained gametocytemic for 
longer: HR 2.42 (95% CI1.39-4.19, P=0.002, Figure 3). The geometric mean gametocyte 
densities were lower in the primaquine group (157/µl, 95% CI 111-222 vs 330/µL, 95% 
CI 197-554; geometric mean ratio 0.47, 95% CI 0.26-0.88, P= 0.018)  
Therapeutic response on asexual stages by Day-42 
Primaquine did not affect asexual stages of P. falciparum. The PCR-unadjusted 
recurrence rates were 1.3% (2 subjects) and 0.6% (1 subject) in the DHP-PQ and DHP-
alone groups (HR=0.87, 95%CI 0.39-1.97, P= 0.913). Molecular genotyping suggested 
that all 3 recurrences were due to re-infections.  
Hemoglobin measurements and adverse events 
Hemoglobin levels were much the same between the two study arms: Day-0: Mean 
difference (MD) (95% CI) -0.09 g/dL (-0.54, 0.36); Day-7: -0.02 g/dL (-0.43, 0.39); 
Day-42: -0.03 g/dL (-0.39, 0.33). The main complaints reported on day-7 were 
headache, fatigue and weakness, nausea and vomiting, abdominal pain, diarrhea, 
pruritus and parasthesia, with similar numbers in both arms (Table 2).  
DISCUSSION 
DHP effectively treated falciparum malaria and successfully prevented the appearance 
of new gametocytes. The addition of a single dose of primaquine reduced gametocyte 
densities and enhanced gametocyte clearance and shortened the median clearance time 
by about 1 week resulting in overall lower gametocyte carriage. By day-14, gametocytes 
were undetectable in all but one patient (0.6%) with primaquine compared to 9.6% (17 
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patients) without. Primaquine had no additional effect against asexual blood stages of P. 
falciparum. These results are consisted with previous reports in symptomatic malaria 
patients treated with artemisinins or ACTs showing that a single dose of primaquine 
suppresses and quickly eliminates persistent mature blood-stage gametocytemia that 
were not affected by the artemisinins[12, 23-24].  
Concerns exist about the potential for a one-off dose of primaquine to induce hemolysis, 
especially in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals[25]. A 
recent study from Tanzania suggested that co-administration of artemisinins with 
primaquine may be associated with mild asymptomatic haemolysis and transient 
reductions in Hb concentrations even in individuals with the wild-type genotype[26]. 
This study used genotyping and screened for the most common mutation associated 
with G6PD deficiency in Tanzania (G6PD A). Since 140 mutations are known to be 
potentially associated with G6PD deficiency one possible explanation suggested by the 
authors is that patients with less common mutations causing G6PD deficiency may have 
been misclassified. Functional screening test based on enzyme activity that measures 
the NADPH production capacity of G6PD, such as used in our study, do not have this 
limitation.  We found that mean hemoglobin concentrations by day 7 and 42 were 
similar in both groups in this selected sample. However, the sample size was too small to 
draw more definitive conclusions about the safety of a single dose of primaquine as the 
study was not designed with safety as primary endpoint and excluded patients with 
G6PD deficiency.  
There is typically a 7 to 15 days delay after the initial acute attack for mature P. 
falciparum gametocytes to become apparent. The timing of the single dose of 
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primaquine is therefore important, especially because with a half-life of about 8 hours 
primaquine is effective only for a few days. In Thailand, gametocytemia peaked 3 days 
after start of treatment with artemisinins and in about of quarter of gametocytemic 
patients they emerged after treatment[27]. The median duration of the history of fever 
prior to treatment was 5 days, consistent with models by Lawpoolsri et al predicting a 
maximum gametocytemia 8 days after the onset of symptoms[19]. In Indonesia, similar 
delays in seeking care are common. We therefore provided primaquine the day after the 
last dose of DHP to maximize the delay of primaquine administration.  
 
There are several study limitations: This was an unblinded study, so all parties involved 
were potentially aware of the treatment allocation. Second, we omitted 14 patients from 
the analysis because 7 randomized to DHP-only were accidentally provided primaquine. 
The allocation sequence concealment was good, and there was no indication that this 
was due to preferential treatment by study-staff. Third, our study reflects the impact on 
microscopically detectable gametocytemia and does not exclude the persistence of sub-
patent gametocytemia detectable by PCR. Our results however are consistent with one 
previous treatment trial in Tanzania suggesting a marked benefit of primaquine in 
clearing submicroscopic gametocytes in symptomatic children receiving sulphadoxine-
pyrimethamine-artsunate [24]. By contrast, another trial in Sudan that aimed to 
eliminate submicroscopic gametocytes in asymptomatic carriers during the dry season 
found no effect of primaquine[28]. They hypothesized that ACTs alone are sufficient to 
clear gametocytes in asymptomatic carriers of sub-microscopic infections, but that 
primaquine is required in patients with acute malaria with higher parasite densities. 
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Although haphazardly implemented, the use of single dose primaquine to reduce 
malaria transmission of falciparum malaria is widely recommended. As countries move 
from malaria control to elimination a better understanding of the risks and benefits of 
adding single-dose primaquine to ACTs, has become increasingly important[23]. 
Because a relatively high proportion of patients had detectable gametocytes on 
enrolment (21%), sick malaria patients constitute a significant source of transmissible 
malaria in this low transmission areas. The addition of primaquine could thus have a 
major effect on malaria transmission from treated patients by shortening the period of 
infectivity, consistent with previous observations in Myanmar[23] and other studies 
looking at the added value of primaquine when provided in addition to ACTs or 
artemisinins[24]. Combined, these findings support recommendations that in settings 
where screening for G6PD deficiency is feasible, a single gametocidal dose of 
primaquine should be added to ACTs in low-transmission regions that aim to control 
and ultimately eliminate falciparum malaria. Further research is needed of primaquine 
as adjunctive gametocidal therapy under more programmatic conditions where routine 
screening for G6PD may not be feasible, including dose-finding studies to determine the 
minimal safe and effective dose. 
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Table 1.  Baseline characteristic of study subjects.                 
Total  Without gametocyte  With gametocyte 
Variables 
DHP + PQ  DHP  DHP + PQ  DHP  DHP + PQ  DHP 
Total subjects  171  178  130  147  41  31 
Male/Female  107/64  107/71  83/47  86/61  24/17  21/10 
Age (years), median (IQR)  20 (11–31)  17 (10–30)  23 (12‐35)  19 (11‐31)  12 (8‐23)  13 (9‐24) 
Body weight (kg), median (IQR)  45.0 (25.0–
55.0) 
45.0 (24.0–
55.0) 
48.5 (33.0‐
58.0) 
45.0 (24.0‐
55.0) 
28.0 (18.0‐
48.5) 
29.0 (20.0‐
50.0) 
Body temperature (oC), mean (SD)  35.7 (0.7)  35.7 (0.6)  35.7 (0.7)  35.7 (0.6)  35.7 (0.7)  35.8 (0.7) 
Fever on Day‐3 (≥ 37.5oC), No. (%)  0 (0%)  1 (0.6%)  0 (0%)   1 (0.7%)  0 (0%)  0 (0%) 
History of duration of illness (days), median 
(IQR) 
3 (2‐5)  3 (2–5)  3 (2‐4)  3 (2‐4)  7 (4‐7)  3 (2‐7) 
Hemoglobin (gr/dL), mean (SD) on Day‐0  13.3 (2.15)  13.3 (2.08)  13.8 (1.93)  13.7 (1.87)  11.5 (1.81)  11.2 (1.77) 
Density of asexual stage (per µL), mean (SD) 
on Day‐3 
 NF   NF   NF   NF   NF   NF  
Gametocytemia on Day‐3, No. (%)   41 (24.0%)  31 (17.4%)  0 (0%)  0 (0%)  41 (100%)  31 (100%) 
Gametocyte density(per µL), median (IQR) 
on Day‐3 
128 (52‐260)  196 (88 ‐552)  NF  NF  128 (52‐260)  196 (88 ‐552) 
History of self‐treatment prior to health 
center, No. (%) 
39 (22.8%)  33 (18.5%)  30 (23.1%)  21 (14.3%)  9 (22.0%)  12 (38.7%) 
Abbreviation: NF= not found, IQR= interquartile range, SD=standard deviation.  
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Table 2. Tolerance of DHP+PQ versus DHP‐alone by Day‐7  
Adverse events  DHP + PQ 
No. (%) 
DHP‐alone 
No. (%) 
RR ( 95% CI)  P value 
Headache  13/97 (13.4%)  18/96 (18.8%)  0.71 (0.37‐1.38)  0.312 
Fatigue  13/93 (14.0%)  11/96 (11.5%)  1.22 (0.58‐2.58)  0.603 
Nausea  1/139 (0.7%)  4/150 (2.7%)  0.27 (0.03‐2.40)  0.205 
Vomiting  1/163 (0.6%)  1/168 (0.6%)  1.03 (0.07‐16.34)  1.000 
Abdominal pain  4/156 (2.6%)  4/170 (2.4%)  1.09 (0.28‐4.28)  1.000 
Diarrhoea  1/163 (0.6%)  3/172 (1.7%)  0.35 (0.04‐3.35)  0.623 
Pruritus  0/170 (0.0%)  0/177 (0.0%)  ‐‐  ‐‐ 
Paresthesia  2/161 (1.2%)  2/170 (1.2%)  1.06 (0.15‐7.41)  1.000 
Evaluable population includes only patients without the symptoms on Day 3.  
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Figure 1. Trial profile 
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Figure 1 notes:  
* All 374 patients who provided informed consent and were screened for G6PD deficiency were found 
to have normal levels of enzyme activity. 
**Five subjects were screening failures: 4 had mixed infections with P. vivax  and 1 was infected by P. 
vivax instead of P. falciparum.  
*** Seven individuals allocated to the DHP‐alone arm were accidently given the DHA‐PQ regimen due to 
human error. In order to maintain the balance within the block randomization, seven subjects 
randomised to DHP+PQ within the same blocks of 4 were also excluded.  
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Figure 2.Gametocyte prevalence and prevalence ratio of the two regimens (black box=DHP+PQ and white box= 
DHP-alone) during 42 days follow up period.  
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Figure 3.Kaplan Meier Survival curves of gametocyte clearance by treatment regimen 
 
 
 
 
 
 
 
